New Covid-19 vaccine designed to be cheap and easy to manufacture has obtained emergency use clearance in India, Texas Children’s Hospital and Baylor College of Medicine said Tuesday.
Dr Peter Hotez, vaccine specialist and co-director of the Texas Children’s Center for Vaccine Development, and co-director Maria Elena Bottazzi, designed the vaccine and manufactured it using traditional vaccine technology.
The idea is to distribute the technology so that developing countries can manufacture the vaccine themselves.
âThis announcement is an important first step in immunizing the world and stopping the pandemic. Our vaccine technology offers a pathway to address an ongoing humanitarian crisis, namely the vulnerability of low- and middle-income countries to the Delta variant, âHotez said in a statement.
âProtein-based vaccines have been widely used to prevent many other diseases, have been proven to be safe, and use economies of scale to achieve low-cost scalability across the world,â Bottazzi said in a statement.
“Our decade-long studies promoting prototype coronavirus vaccines led to the creation of this vaccine, which will fill the access gap created by the most expensive and newer vaccine technologies and which, today, ‘ hui, are still not able to be rapidly scaled up for global production, âshe added.
Hotez told CNN’s Poppy Harlow they were “over the moon this morning” after Indian regulators announced the clearance alongside vaccine-producing partners.
âThis is the first Covid vaccine specifically for global health, for low- and middle-income countries around the world. It’s a recombinant vaccine that uses similar technology that makes the hepatitis B vaccine, âhe added.
âThey now have 150 million doses ready to use and are now producing 100 million doses per month with plans to produce a billion doses. To date, our Texas Children’s Center for Vaccine Development in Baylor has matched or doubled the U.S. government’s commitment to global health equity. It’s so exciting for us, âHotez told CNN.
Learn more about the vaccine: The vaccine, called Corbevax, has been tested on 3,000 volunteers in two trials, the hospital said. No serious adverse events were seen, the hospital said, and trials showed people developed an immune response that should correlate with 90% or better protection against the original coronavirus strain and 80% against the Delta strain to prevent symptomatic diseases.
It’s made from a piece of genetically modified coronavirus grown in yeast, combined with immune system boosting compounds called adjuvants. He was licensed by BCM Ventures, the marketing team at Baylor College of Medicine, to Biological E. Limited based in Hyderabad, India.
See Bottazzi’s tweet on the vaccine: